Manufacturer record
Macleods Pharmaceuticals Ltd. Kh. No. 21: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
1 batch manufactured by Macleods Pharmaceuticals Ltd. Kh. No. 21 (Sikkim) was declared Not of Standard Quality in February 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: 18252131A, Cefixime Tablets IP (exp Oct 2027). FDTL,Uttarakhand (state lab) found it not of standard quality: Storage-Does not comply with IP. Listed in the February 2026 alert.
Records by type
1 record linked to Macleods Pharmaceuticals Ltd. Kh. No. 21 in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Cefixime Tablets IP | Batch 18252131AMfg May 2025 · Exp Oct 2027 | Storage-Does not comply with IPOther | FDTL,UttarakhandState lab | Feb 2026 |
Batches reported as suspected spurious under this label
CDSCO's spurious-drug alerts list batches that purport to be made by a company but are suspected counterfeits. The labelled manufacturer's reply is shown where CDSCO published it.
| Product | Batch | Reported by | Firm's reply | Alert |
|---|---|---|---|---|
| Deflazacort Tablets 6 mg Defcort 6 | 13240334A | RDTL, Chandigarh | The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. | Dec 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.